Eric Palmer

Biography for Eric Palmer

Eric Palmer, Senior Editor

Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at epalmer@fiercemarkets.com.

Articles by Eric Palmer

Pfizer could buy GSK, but would Shire or Perrigo offer better targets?

The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.

Celgene's next-gen psoriasis drug dissed by German cost watchdog

Celgene's Otezla has hit a snag with the notoriously difficult German cost watchdog IQWiG, which said it just doesn't see the added benefit over treatments already on the market.

Hep C landscape shifts again as BMS combo nabs breakthrough tag

Gilead Sciences and AbbVie caught a break for their hepatitis C treatments when the FDA rescinded breakthrough designations earlier this year for potential competitors being developed by Merck and Bristol-Myers Squibb.

AstraZeneca, betting on biologics, will build a $285M facility in Sweden

AstraZeneca CEO Pascal Soriot is counting on the company's cancer drug pipeline to help it climb out of the revenue hole it has fallen into, and he figures his company needs more manufacturing capacity for the coming launches.

Actavis talks to DOJ about resolving probe of Warner Chilcott marketing misdeeds

Actavis is trying to rid itself of some nasty legal entanglements that it picked up in its $8.5 billion deal for Ireland's Warner Chilcott, meeting with the Justice Department looking for a way to put to rest an investigation into allegations Warner Chilcott essentially bribed doctors into prescribing some of its meds.

New CEO Weber deals with Takeda's loss and promises brighter future

In his debut earnings report since assuming his role as CEO of Japanese drugmaker Takeda, Christophe Weber had to tell investors today that the company had a small loss in its last fiscal year.

Senator asks VA to yank patent on Gilead's Sovaldi to crush its price

Gilead Sciences has been able to withstand scathing criticism at home over the prices of its hep C cures, negotiate with stingy price watchdogs abroad and face down criticism in developing countries by giving generics producers access to formulations and technology. But can it stand up to a possible attack by the U.S. military?

Alexion adding a plant and a couple hundred jobs to its budding Irish base

Rare disease drugmaker Alexion has found a lot to love in Ireland. Taking advantage of that country's generous tax rate, it has turned that country into its European base of operations. With a pipeline of new drugs brewing, the rare disease specialist now intends to build a new plant and add a couple hundred more workers there.

Pfizer settles lawsuits tying sex and gambling addictions to dopamine meds

Pfizer is settling class-action litigation brought by patients who claimed the drugmaker did not adequately warn them of possible side effects of drugs they were taking to treat their Parkinson's disease or restless leg syndrome.

Amarin sues FDA over 'free speech' issue the agency says it is ready to hash out

Irish drugmaker Amarin, which reported another quarterly loss today, has sued the FDA for curtailing its free speech, namely being able to discuss off-label uses of its omega-3 capsule Vascepa that might spur some sales.